RE: Some mistakes made25 Jan 2024 12:15
What about:-
==========================
ANY Company in the ENTIRE WORLD doing cancer research surely MUST BUY the Parsortix machine? It enables them to more cheaply and more accurately MONITOR the effect of the treatment they are trialing by simply testing the captured circulating cancer cells parsortix can catch from the patients standard blood sample. I honestly cannot see how itis even possible for sales of the machine not to rapidly increase. It's just a complete no-brainer.
==========================
Sure they have made massive mistakes in the past. That is why the sp nose dived to 10p.
The relatively new approach, offering analysing the CCT's in their own lab to show how it is done, the new assays to make it far easier for labs all over the World to buy and use the parsortix machines, the huge potential with the Molecule analysys side (just 1 big deal here could be transformational for Angle), the huge potential with the Bioview/HER2 deal etc.... As you say the list goes on and on.......
Strengthening the sales force employing Brett Swansiger was a really good idea as clearly with a unique machine to sell something was very wrong on the sales side. Developing some key assay kits to sell with the machine was also deperately needed (seems originally they thought the buyers of the parsortix machines would do this, and for the most part they did not, or found it difficult/expensive). The good thing here is Angle sell the assay kits too, so another source of income! The more assay kits they develop and sell the more £££. That is apart from the machine itself and the all important cassetts it uses each time a blood sample is processed.............
It's going to be a huge winner I think.
All IMHO.
Sign In
Follow the stocks
